Sheng Kuo-Ching, Pietersz Geoff A, Wright Mark D, Apostolopoulos Vasso
The Austin Research Institute, Immunology and Vaccine Laboratory, Heidelberg, VIC, Australia.
Curr Med Chem. 2005;12(15):1783-800. doi: 10.2174/0929867054367248.
There is an increasing number of studies utilizing dendritic cell (DC) based therapies for cancer. With a powerful antigen-presentation capability, DCs have the potential to overcome tumor tolerance and induce anti-tumor immunity, when loaded with tumor antigens. In order to optimize this approach, methods have aimed to enhance immunopotency of therapeutic DCs. A thorough understanding of DC immunobiology would accelerate this process and provide advantageous procedures to increase anti-tumor responses. This review contains an analysis of recent advances on DC subsets, phenotypic characterization, localization, surface receptors and their ligands. The events of immune induction via DCs, involving initial recognition and uptake of antigens, migration, subsequent activation and maturation are revisited. Furthermore, the current methods used for DC-based cancer immunotherapy, including DCs pulsed with tumor antigens in forms of DNA, RNA, peptides, proteins and lysates, or DCs fused with tumor cells are summarized. Respective preclinical and clinical trials are in progress and hold promise for developing effective cancer vaccines.
利用基于树突状细胞（DC）的疗法治疗癌症的研究越来越多。由于具有强大的抗原呈递能力，当负载肿瘤抗原时，DC有潜力克服肿瘤耐受性并诱导抗肿瘤免疫。为了优化这种方法，人们致力于增强治疗性DC的免疫效力。深入了解DC免疫生物学将加速这一进程，并提供增加抗肿瘤反应的有利程序。这篇综述分析了DC亚群、表型特征、定位、表面受体及其配体的最新进展。回顾了通过DC进行免疫诱导的过程，包括抗原的初始识别和摄取、迁移、随后的激活和成熟。此外，还总结了目前用于基于DC的癌症免疫治疗的方法，包括用DNA、RNA、肽、蛋白质和裂解物等形式的肿瘤抗原脉冲处理的DC，或与肿瘤细胞融合的DC。各自的临床前和临床试验正在进行中，有望开发出有效的癌症疫苗。
